Verve Therapeutics Inc’s recently made public that its Chief Administrative Officer Nickerson Joan unloaded Company’s shares for reported $12475.0 on Apr 02 ’24. In the deal valued at $8.24 per share,1,514 shares were sold. As a result of this transaction, Nickerson Joan now holds 8,659 shares worth roughly $65808.4.
Then, Dorval Allison sold 554 shares, generating $6,343 in total proceeds. Upon selling the shares at $11.45, the Chief Financial Officer now owns 4,060 shares.
H.C. Wainwright initiated its Verve Therapeutics Inc [VERV] rating to a Buy in a research note published on April 08, 2024; the price target was $15. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who began to cover the stock in mid April with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering VERV with “Neutral” recommendation on February 01, 2023. Goldman started covering the stock on December 15, 2022. It rated VERV as “a Sell”.
Price Performance Review of VERV
On Friday, Verve Therapeutics Inc [NASDAQ:VERV] saw its stock fall -5.82% to $7.60. Over the last five days, the stock has lost -10.80%. Verve Therapeutics Inc shares have fallen nearly -45.48% since the year began. Nevertheless, the stocks have fallen -44.49% over the past one year. While a 52-week high of $21.42 was reached on 02/29/24, a 52-week low of $7.36 was recorded on 04/02/24. SMA at 50 days reached $12.66, while 200 days put it at $13.75. A total of 1.19 million shares were traded, compared to the trading of 1.08 million shares in the previous session.
Levels Of Support And Resistance For VERV Stock
The 24-hour chart illustrates a support level at 7.42, which if violated will result in even more drops to 7.24. On the upside, there is a resistance level at 7.90. A further resistance level may holdings at 8.20. The Relative Strength Index (RSI) on the 14-day chart is 24.81, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -2.13, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 96.24%. Stochastics %K at 8.13% indicates the stock is a buying.
The most recent change occurred on October 06, 2022 when Credit Suisse began covering the stock and recommended ‘”a Neutral”‘ rating along with a $48 price target.
